{"doc_id": "32706953", "type of study": "Therapy", "title": "", "abstract": "Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.\nHydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19).\nHowever, evidence on the safety and efficacy of these therapies is limited.\nWe conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen.\nPatients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days.\nThe primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified intention-to-treat population (patients with a confirmed diagnosis of Covid-19).\nSafety was also assessed.\nA total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis.\nAs compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P\u2009=\u20091.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P\u2009=\u20091.00).\nProlongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent.\nAmong patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. (Funded by the Coalition Covid-19 Brazil and EMS Pharma; ClinicalTrials.gov number, NCT04322123.).\nCopyright \u00a9 2020 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Mild-to-Moderate Covid-19", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 76}, {"term": "hospitalized patients", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 117}, {"term": "suspected or confirmed Covid-19", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 154}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 85}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 27}, {"term": "mild-to-moderate Covid-19", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 58}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 .", "Evidence Elements": {"Participant": [{"term": "Mild-to-Moderate Covid-19", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 76}], "Intervention": [{"term": "Hydroxychloroquine with or without Azithromycin", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 47}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 ( Covid-19 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "However , evidence on the safety and efficacy of these therapies is limited .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We conducted a multicenter , randomized , open-label , three-group , controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen .", "Evidence Elements": {"Participant": [{"term": "hospitalized patients", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 117}, {"term": "suspected or confirmed Covid-19", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 154}], "Intervention": [{"term": "no supplemental oxygen", "negation": "affirmed", "UMLS": {}, "start": 181, "end": 203}, {"term": "maximum of 4 liters per", "negation": "negated", "UMLS": {}, "start": 209, "end": 232}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned in a 1:1:1 ratio to receive standard care , standard care plus hydroxychloroquine at a dose of 400 mg twice daily , or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 73}, {"term": "standard care plus hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 113}, {"term": "standard care plus hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 113}, {"term": "400", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 130}, {"term": "daily plus azithromycin", "negation": "affirmed", "UMLS": {}, "start": 215, "end": 238}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale ( with levels ranging from one to seven and higher scores indicating a worse condition ) in the modified intention-to-treat population ( patients with a confirmed diagnosis of Covid-19 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "clinical status at 15", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 45}, {"term": "seven-level ordinal scale", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 106}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Safety was also assessed .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "A total of 667 patients underwent randomization ; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis .", "Evidence Elements": {"Participant": [{"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 85}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "As compared with standard care , the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone ( odds ratio , 1.21 ; 95 % confidence interval [ CI ] , 0.69 to 2.11 ; P=1.00 ) or hydroxychloroquine plus azithromycin ( odds ratio , 0.99 ; 95 % CI , 0.57 to 1.73 ; P=1.00 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 30}, {"term": "hydroxychloroquine alone", "negation": "negated", "UMLS": {}, "start": 151, "end": 175}, {"term": "hydroxychloroquine plus azithromycin", "negation": "negated", "UMLS": {}, "start": 259, "end": 295}], "Outcome": [{"term": "proportional odds of having a higher score on the seven-point ordinal scale at 15 days", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 123}], "Observation": [{"term": "affected", "negation": "negated", "UMLS": {}, "start": 132, "end": 140}], "Count": []}, "Evidence Propositions": [{"Intervention": "standard care", "Observation": "affected", "Outcome": "proportional odds of having a higher score on the seven-point ordinal scale at 15 days", "Count": ""}, {"Intervention": "hydroxychloroquine alone", "Observation": "affected", "Outcome": "proportional odds of having a higher score on the seven-point ordinal scale at 15 days", "Count": ""}, {"Intervention": "hydroxychloroquine plus azithromycin", "Observation": "affected", "Outcome": "proportional odds of having a higher score on the seven-point ordinal scale at 15 days", "Count": ""}]}, {"Section": "RESULTS", "Text": "Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine , alone or with azithromycin , than in those who were not receiving either agent .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 120, "end": 138}, {"term": "azithromycin", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 167}], "Outcome": [{"term": "Prolongation of the corrected QT interval", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 41}, {"term": "elevation of liver-enzyme levels", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 78}], "Observation": [{"term": "more frequent", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 97}], "Count": []}, "Evidence Propositions": [{"Intervention": ["hydroxychloroquine", "azithromycin"], "Observation": "more frequent", "Outcome": "Prolongation of the corrected QT interval", "Count": ""}, {"Intervention": ["hydroxychloroquine", "azithromycin"], "Observation": "more frequent", "Outcome": "elevation of liver-enzyme levels", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "Among patients hospitalized with mild-to-moderate Covid-19 , the use of hydroxychloroquine , alone or with azithromycin , did not improve clinical status at 15 days as compared with standard care . ( Funded by the Coalition Covid-19 Brazil and EMS Pharma ; ClinicalTrials.gov number , NCT04322123 . ) .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 27}, {"term": "mild-to-moderate Covid-19", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 58}], "Intervention": [{"term": "hydroxychloroquine , alone or with azithromycin", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 119}, {"term": "standard care", "negation": "negated", "UMLS": {}, "start": 182, "end": 195}], "Outcome": [{"term": "clinical status", "negation": "negated", "UMLS": {}, "start": 138, "end": 153}], "Observation": [{"term": "improve", "negation": "negated", "UMLS": {}, "start": 130, "end": 137}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}